ArticleDrug design, development and therapy2025
Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study.
Jinyu Xiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.